Get the Stockscreener App
2.45
0.81%
-0.02
Pre-market:
2.44
-0.01
-0.41%
Ovid Therapeutics Inc stock is traded at $2.45, with a volume of 1.09M.
It is down -0.81% in the last 24 hours and down -5.77% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$2.47
Open:
$2.45
24h Volume:
1.09M
Relative Volume:
0.36
Market Cap:
$457.27M
Revenue:
$7.25M
Net Income/Loss:
$-17.41M
P/E Ratio:
-9.3262
EPS:
-0.2627
Net Cash Flow:
$-38.33M
1W Performance:
+2.08%
1M Performance:
-5.77%
6M Performance:
+50.31%
1Y Performance:
+758.75%
1-Day Range:
$2.39
$2.505
1-Week Range:
$2.33
$2.515
52-Week Range:
$0.2701
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.45 | 461.00M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Roth Capital | Buy |
| Nov-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan
Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan
Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan
Balyasny group holds 5.33% of Ovid (NASDAQ: OVID) across funds - Stock Titan
[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com India
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
OVID Sets Stage for Future Growth with Promising Pipeline Develo - GuruFocus
Ovid Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Ovid Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ovid Therapeutics Reports Q1 2026 Results, Advances OV329 and OV4071 Clinical Programs, and Expands Pipeline for Pediatric Epilepsy and Psychosis 123 - Minichart
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress By Investing.com - Investing.com South Africa
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress - Investing.com UK
OVID: Advancing novel therapies for seizures and psychosis with strong safety and market potential - TradingView
Ovid Therapeutics : May 2026 Corporate Presentation - marketscreener.com
Ovid Therapeutics Q1 net loss widens as R&D spending rises - TradingView
Ovid Therapeutics Inc. 1Q 2026: Revenue $0M, Net loss $17M, EPS $(0.12) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Ovid Therapeutics (NASDAQ: OVID) widens Q1 loss but boosts cash to $165.6M - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) extends cash runway into 2029 - Stock Titan
TradingKey - TradingKey
Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks - Insider Monkey
Ovid Therapeutics (OVID) Eps Diluted (TTM) - Zacks Investment Research
5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey
Ovid Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
MSN Money - MSN
Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest - MarketBeat
OVID Earnings History & Surprises | EPS & Revenue Results | OVID THERAPEUTICS INC (NASDAQ:OVID) - ChartMill
Ovid Therapeutics (NASDAQ: OVID) outlines 2026 virtual meeting, pay and audit votes - Stock Titan
SEC Form DEFA14A filed by Ovid Therapeutics Inc. - Quantisnow
[ARS] Ovid Therapeutics Inc. SEC Filing - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) registers 29.9M resale shares from private placement - Stock Titan
[EFFECT] Ovid Therapeutics Inc. SEC Filing - Stock Titan
OVID Ovid Therapeutics Inc. far exceeds Q4 2025 EPS expectations, shares rise nearly four percent.Profit Guidance - Cổng thông tin điện tử Tỉnh Sơn La
OVID (Ovid Therapeutics) delivers blowout Q4 2025 results, but stock dips slightly amid mild investor profit taking.Deceleration Risk - Xã Thanh Hà
29.86M-share resale registration by Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):